- of
effect size, the NNT was
described in 1988 by
McMaster University's
Laupacis,
Sackett and Roberts.
While theoretically, the
ideal NNT is 1,
where everyone...
- doi:10.1001/jama.1994.03510350037034. PMID 8114236.
Stiell I,
Wells G,
Laupacis A, et al. (September 1995). "Multicentre
trial to
introduce the Ottawa...
- PMID 32019751.
Stiell IG,
Wells GA,
Vandemheen K,
Clement C,
Lesiuk H,
Laupacis A, et al. (May 2001). "The
Canadian CT Head Rule for
patients with minor...
- 127. PMID 26404748.
Juurlink DN,
Mamdani MM, Lee DS, Kopp A,
Austin PC,
Laupacis A, et al. (August 2004). "Rates of
hyperkalemia after publication of the...
-
Archived from the
original on 18
November 2010.
Retrieved 13 July 2011.
Laupacis A,
Keown PA, Ulan RA,
McKenzie N,
Stiller CR (May 1982). "Cyclosporin A:...
- 127. PMID 26404748.
Juurlink DN,
Mamdani MM, Lee DS, Kopp A,
Austin PC,
Laupacis A,
Redelmeier DA (August 2004). "Rates of
hyperkalemia after publication...
- doi:10.7326/0003-4819-124-4-199602150-00005. PMID 8554250. S2CID 25470460.
Laupacis,
Andreas (1997). "Clinical
prediction rules: a
review and
suggested modifications...
-
Institute (retired,
April 2004) and Senator,
Senate of
Canada Dr.
Andreas Laupacis,
President and
Chief Executive Officer,
Institute for
Clinical Evaluative...
-
Douglas S.; Rochon,
Paula A.; Kopp, Alex; Naglie, Gary; Austin,
Peter C.;
Laupacis, Andreas; Stukel, Thérèse A. (2004-05-29). "Cyclo-oxygenase-2 inhibitors...
-
start reading them critically". Can Med ****oc J. 124 (555): 558. 1981.
Laupacis A,
Sackett DL,
Roberts RS (June 1988). "An ****essment of
clinically useful...
